collaborations
In December 2004, Addex Pharmaceuticals entered into a collaboration and licence agreement with Ortho-McNeil, a Johnson & Johnson company. to discover and develop positive allosteric modulators (PAM) of metabotropic glutamate receptor 2 (mGluR2). The mGluR2 PAM approach is a clinically validated strategy in both anxiety and schizophrenia.
In December 2007, Addex entered into an exclusive license and collaboration agreement with Merck & Co. affiliate Merck Sharp & Dohme to discover and develop mGluR4 PAM. The partnership includes a number of mGluR4 PAM discovered at Addex. Merck is responsible for preclincal and clinical development.
In January 2008, Addex entered an exclusive worldwide license agreement with Merck & Co., Inc. to develop ADX63365, an orally available drug candidate for the potential treatment of schizophrenia and other undisclosed indications.
Addex Pharma is seeking partners for several other products in its pipeline.